CGM OK'd During Medical Imaging; All Semaglutide Doses Back; Bariatric Surgery Down

— News and commentary from the endocrinology world

by Kristen Monaco, Senior Staff Writer, �鶹��ý November 5, 2024

Endo Break over a computer rendering of a man with illustrated body organs.

Abbott's FreeStyle Libre 2 and 3 are the first and only patient-applied continuous glucose monitoring (CGM) systems to be approved , the company said.

In related news, the American Diabetes Association released new consensus considerations and good-practice points for in hospital settings. (Diabetes Care)

A from the Androgen Society said "it has now been conclusively determined that testosterone therapy is not associated with increased risks of heart attack, stroke, or cardiovascular death." The position was supported by the TRAVERSE trial findings. (Mayo Clinic Proceedings)

All doses of semaglutide (Ozempic, Wegovy) are , according to an update in the FDA's drug shortage database. (CNBC)

AstraZeneca's was safe and tolerable in a 72-patient phase I trial, yielding an average 5.8% weight loss within 4 weeks, the company announced at ObesityWeek. (Reuters via MSN)

Also out of the meeting, its investigational GLP-1/GIP agonist tablet led to an average 6.8% placebo-adjusted weight loss at day 28 in a phase I study. Catch up on more research from ObesityWeek here.

from 2022 to 2023 amid a rise in prescriptions for GLP-1 receptor agonists. (JAMA Network Open)

People with type 2 diabetes who started an SGLT2 inhibitor had a significantly compared with those starting on GLP-1 agonists. (The BMJ)

Obesity treatments over 2 years, an analysis of U.S. health insurance claims showed. (Reuters)

Adding semaglutide to standard of care helped improve liver fibrosis and in a placebo-controlled phase III trial, said Novo Nordisk.

Low-calorie diets involving fasting , according to a pilot trial of 13 people with chronic kidney disease. (Science Translational Medicine)

The of drugs compounded and distributed by Fullerton Wellness in California, including semaglutide and tirzepatide, as they may not be sterile.

Nonsmokers who started menopause between ages 40-44 had compared with women who started menopause between ages 50-54, suggesting "the role of estrogen in increasing risk of asthma," said researchers in Menopause.

High intensity exercise , a marker of hunger, a study of 14 adults found. (Journal of the Endocrine Society)

Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.